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Abstract
The pathogenesis of SARS coronavirus (CoV) remains poorly understood. In the current study, two recombinant baculovirus
were generated to express the spike (S) protein of SARS-like coronavirus (SL-CoV) isolated from bats (vAcBS) and the
envelope (E) and membrane (M) proteins of SARS-CoV, respectively. Co-infection of insect cells with these two recombinant
baculoviruses led to self-assembly of virus-like particles (BVLPs) as demonstrated by electron microscopy. Incorporation of S
protein of vAcBS (BS) into VLPs was confirmed by western blot and immunogold labeling. Such BVLPs up-regulated the level
of CD40, CD80, CD86, CD83, and enhanced the secretion of IL-6, IL-10 and TNF-a in immature dendritic cells (DCs). Immune
responses were compared in immature DCs inoculated with BVLPs or with VLPs formed by S, E and M proteins of human
SARS-CoV. BVLPs showed a stronger ability to stimulate DCs in terms of cytokine induction as evidenced by 2 to 6 fold
higher production of IL-6 and TNF-a. Further study indicated that IFN-c+ and IL-4+ populations in CD4+ T cells increased
upon co-cultivation with DCs pre-exposed with BVLPs or SARS-CoV VLPs. The observed difference in DC-stimulating activity
between BVLPs and SARS CoV VLPs was very likely due to the S protein. In agreement, SL-CoV S DNA vaccine evoked a more
vigorous antibody response and a stronger T cell response than SARS-CoV S DNA in mice. Our data have demonstrated for
the first time that SL-CoV VLPs formed by membrane proteins of different origins, one from SL-CoV isolated from bats (BS)
and the other two from human SARS-CoV (E and M), activated immature DCs and enhanced the expression of co-
stimulatory molecules and the secretion of cytokines. Finding in this study may provide important information for vaccine
development as well as for understanding the pathogenesis of SARS-like CoV.
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Introduction
Severe acute respiratory syndrome (SARS) is an emerging
infectious disease caused by a novel coronavirus (CoV) variant,
SARS CoV [1–5]. During the 2002–2003 epidemic, SARS CoV
was highly transmissible in humans. As of 31 December 2003,
8,096 cases had been identified worldwide and 774 people had
died with a mortality rate of about 9.6% (World Health
Organization statistics (http://www.who.int/csr/sars/country/
table 2004_04_21/en/). Although the SARS epidemic was
successfully contained by July 2003, the pathogenesis of SARS
CoV remains poorly understood.
The viral envelope of SARS CoV contains at least three
structural membrane proteins, spike (S), membrane (M), and small
membrane or envelope (E) proteins [6,7]. The cellular receptor of
SARS CoV and the receptor-binding domain (RBD) on S protein
have been identified, indicating that RBD in the S1 region of S
protein plays a critical role in neutralizing antibody induction,
angiotensin-converting enzyme 2 (ACE-2) binding and viral entry
[8–10]. In the absence of S protein, expression of M and E
proteins does not induce a detectable serum SARS-CoV-
neutralizing antibody response [11]. M and E proteins are the
only requirements for the assembly of viral particles; the S protein
is dispensable but is incorporated when present [12–16].
The isolation of SARS CoV from Himalayan palm civets
(Paguma larvata) and raccoon dogs (Nyctereutes procyonoides) in wild live
markets in China suggests that the virus may be originally from
animal reservoirs [17]. Recently, two independent groups reported
the identification of SARS-like coronavirus (SL-CoV) in different
Chinese horseshoe bat species, providing strong evidence that bats
could serve as natural reservoirs of SARS CoV [18–20]. The S
coding sequence of SL-CoV isolated from bats displays low level of
similarity to those isolated from human (76%) or civets (78%) [18–
20], while the E and M proteins of SL-CoV have high sequence
similarity (96% to 100%) to those from human or civets [19,20]. It
is worthy to note that the nucleotide sequence identity among
these coronaviruses from different sources was greatly increased
when the S region was excluded [19,20]. The host range of
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protein variations [21], suggesting that the variations in S protein
are responsible for the interspecies transmission and the
adaptation to new hosts.
Virus-like particles (VLPs) represent a specific class of subunit
vaccine that mimics the structure of authentic virus particles. VLPs
present viral antigens in a more authentic conformation than other
subunit vaccines and are readily recognized by the immune system
[22]. Many studies have documented that VLPs are capable of
inducing B-cell-mediated immune responses and are highly
effective in stimulating CD4 T cell proliferation and cytotoxic T
lymphocyte (CTL) responses [23–25]. The stimulating activities of
Ebola, Marburg and HIV VLPs in dendritic cells (DCs) were
previous investigated [26–28], indicating that, unlike native virus,
VLPs are effective stimulators of DCs and can enhance innate and
adaptive immune responses. Our previous study described that
VLPs formed by E, M and S proteins of SARS CoV elicited strong
SARS CoV-specific humoral and cellular immune responses in
mice [29]. However, whether SL-CoV VLPs can elicit cytokines
secretion or/and activate human DCs remains to be determined.
In this study, we have investigated whether the S protein of SL-
CoV isolated from bats can incorporate into VLPs formed by the
E and M proteins of human SARS CoV. In addition, because in
vitro infection model of bat SL-CoV has not so far been
established, we intended to use VLPs as an alternative to study
the immune responses induced in DCs. Therefore, we compared
the phenotypic and functional changes of immature DCs
inoculated with BVLPs or with SARS CoV VLPs. The S-specific
immune activation was further confirmed in mice using S DNA
vaccines. Findings described in this report may have significance
for understanding the evolution and the pathogenesis of SARS
CoV.
Results
Construction of BVLPs
The bs gene was amplified by RT-PCR and cloned into
pFastBac DUAL vector. The recombinant baculovirus vAcBS was
generated following transfection in sf21 cells. The recombinant
baculovirus vAcME, expressing the E and M proteins of SARS
CoV WH20 strain (GenBank accession number AY772062), was
previously described [29].
VLPs formed by the S, E and M proteins of SARS CoV were
successfully constructed in our previous study using a baculovirus
system [30]. The main variation between SL-CoV and SARS
CoV of human or civet locates in the S protein [18–20]. To study
whether BS protein can be incorporated into VLPs formed by the
E and M proteins of SARS-CoV, we co-infected sf21 cells with the
recombinant baculoviruses vAcBS and vAcME. After 72 h of co-
infection, the cells were collected and thin-sections were prepared
and examined. As shown in Figure 1A, numerous viral particles,
,100 nm in diameter, were mainly observed in the cytoplasm of
infected cells. Western blot and immunogold labeling were
subsequently performed to detect the incorporation of BS in
VLPs. As shown in Figure 1B, the presence of BS, M and E
proteins was detected in BVLPs by using an anti-SARS CoV
antibody. There were no corresponding bands in the negative
control of preimmune rabit antiserum. The genomic differences
between SL-CoV and SARS CoV largely locate in the S gene,
particularly at the 59 end of S region (equivalent to S1 coding
region). Therefore, it is not surprising that serum raised against
human SARS CoV recognized bat SL-CoV S protein. The S2
coding region of S protein is highly conserved (,96%) [5,10,21].
Using a specific anti-BS2 (Bat S2 region 667–1242 aa) antibody
(Figure 1C), the gold particles were detected around the BVLPs in
immunogold labeling analysis, further confirming the results of
western blot. In addition, the anti-BS2 antibody also recognized
the human SARS CoV VLPs but not VLPs formed by E and M
proteins in the absence of S protein (Figure 1C). Taken together,
our data indicate that the BS protein of SL-CoV was successfully
incorporated into VLPs formed by the E and M proteins of human
SARS CoV.
Phenotype characterization of DCs treated with BVLPs
Immature DCs were incubated with 10 mg/ml BVLPs for 16 h.
The expression of costimulatory molecules (CD40, CD86 and
CD80) and the maturation marker CD83 were analyzed. DCs
treated with PBS or Ac were used as negative controls. As shown
in Fig. 2, similar to those on LPS-treated DCs, all of the four
markers were up-regulated to much higher levels than those on
PBS or Ac-treated DCs (Fig. 2). Collectively, our results indicate
that BVLPs can lead to the activation and maturation of DCs. In
contrast, the heated BVLPs induced much lower levels of CD83,
CD40, CD86 and CD80 expression on DCs, suggesting that the
structural proteins incorporated into VLPs are essential for DC
activation and maturation.
Assays of cytokines in BVLPs stimulated DCs
DC maturation not only leads to up-regulation of adhesion and
co-stimulatory molecules, but also results in secretion of proin-
flammatory cytokinesthat canactivateinnate and adaptive immune
responses [31]. To assess the effects of BVLPs on DCs, immature
DCs were treated under various conditions and supernatants were
collected for cytokine (IL-6, IL-10 and TNF-alpha) quantification.
IL-6 and TNF-a are proinflammatory cytokines while IL-10 is an
anti-inflammatory cytokine. As shown in Fig. 3, incubating DCs
withBVLPssignificantlyenhanced thesecretion levelsof thesethree
cytokines and were all similar to those in LPS-treated DCs. The
boiled-BVLPs lost the ability to induce cytokine production. The
secretions of IL-6, IL-10 and TNF-a were 5–10 folds lower in
heated BVLPs-treated DCs than those in BVLPs-treated DCs,
although the secretion levels were still 5–15 folds higher than those
in PBS or Ac treated groups. This enhancement is likely due to non-
specific stimulation by remaining denatured proteins in heated
BVLPs. Moreover, cytokine secretion profiles were similar in DCs
inoculated with BVLPs with or without polymyxin B pretreatment,
excluding the possibility of LPS contamination. In contrast, LPS-
treated DCs significantly lost the cytokine-secretion ability with
polymyxin B pretreatment. Combining the flow cytometry results in
Fig. 2, it is reasonable to draw a conclusion that the structure of
BVLPs, not LPS contamination, contributed to cytokine production
in BVLPs-treated DCs.
Phenotypic and functional changes of DCs treated with
BVLPs or SARS CoV VLPs
We previously constructed SARS CoV VLPs and investigated
the humoral and cellular immune responses induced by SARS
CoV VLPs in mice [29]. Whether SARS CoV VLPs can activate
DCs remains to be addressed. In the current study, 10 mg/ml of
either SARS CoV VLPs or BVLPs was incubated with immature
DCs, and the expression of surface makers and the secretion of
cytokines were subsequently analyzed. Similar to LPS treatment,
both SARS CoV VLPs and BVLPs enhanced the expression of
CD40, CD86, CD80 and CD83 (Fig. 4). However, BVLPs showed
a stronger ability to induce the secretion of IL-6 and TNF-a, with
2 and 4 fold higher, respectively, while the secretion of IL 10 was
similar (Fig. 5). Because the only difference between SARS CoV
VLPs of SL-CoV Stimulate DCs
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TNF-a induction is highly likely due to the variation between the
two S proteins.
TH1/TH2 differentiation of T cells stimulated by DCs
treated with BVLPs or SARS CoV VLPs
To understand the types of T cells stimulated by VLPs-exposed
DCs, IFN-c and IL-2 intracellular staining was measured by flow
cytometry. As show in Fig. 6, IFN-c+ population in CD4+ T cells
stimulated by either BVLPs- or SARS CoV VLPs-treated DCs
were much higher than IL-4+ popoulation. In PBS- or Ac-treated
groups, the percentage between IFN-c+ and IL-4+ populations in
CD4+ T cells did not have significant difference. Thus, the BVLPs
or SARS CoV VLPs treated DCs could polarize Th cells toward a
Th1 phenotype. The balance between Th1 and Th2 responses to
an infectious agent can influence both pathogen growth and
immunopathology. Th1-dominant cellular immunity may be a
crucial factor for long-term protection against virus infection.
S-specific antibody and Th1/Th2 type responses
The observed difference in DC-stimulating activity between
SARS CoV VLPs and BVLPs was very likely due to the S protein.
To further confirm our conclusion, we cloned s and bs gene into
pcDNA3.1 to construct the recombinant plasmids pcDNA-S and
pcDNA-BS, respectively. These two plasmids were then immu-
nized in mice intramuscularly every two weeks. Ten days after the
final immunization, IgG1 and IgG2a were measured to determine
the humoral immune response profiles by ELISA. As shown in
Figure 1. Confirmation of the incorporation of BS protein in BVLPs. (A) Budding of BVLPs from insect cells. Sf21 cells were co-infected with
recombinant baculovirus vAcBS and vAcME at a moi of 5. At 72 h post-infection, cells were harvested and fixed with 2% glutaraldehyde and then
with 1% osmium tetroxide. Thin-section samples were prepared and stained with 1% uranyl acetate followed by examination under a transmission
electron microscope. Arrows indicates BVLPs. Bar=250 nm. (B) Western blot analysis of BVLPs. 5 mg purified BVLPs were analyzed by western blot
using rabbit-derived anti-SARS-CoV antibody. An equivalent amount of purified human SARS CoV VLPs was run in parallel. Preimmune rabbit
antiserum was used as negative control. Left part, band corresponds to S protein. Lane 1, negative control; lane 2, human SARS CoV VLPs; lane 3,
BVLPs. Right part, band corresponds to E or M protein. Lane 1, human SARS CoV VLPs; lane 2, negative control; lane 3, BVLPs. The protein marker was
Fermentas #SM0671. (C) Detection of BVLPs by immunogold labeling. The collodion-coated EM grids were loaded with purified BVLPs (left), SARS
CoV VLPs (middle) or VLPs without BS or S protein (right) for 5 min. After removal of the excess sample solution, grids were incubated with antibody
specific against BS2 protein for 1 h and then incubated with 15 nm gold conjugated anti-rabbit IgG.. The samples were stained with 2% PTA for
1 min, drained and examined under the EM. Arrow indicates the gold particles and triangle indicates the VLPs. Bar=100 nm.
doi:10.1371/journal.pone.0002685.g001
VLPs of SL-CoV Stimulate DCs
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IgG1 and IgG2a were induced in all the immunization regimens.
Although the level of IgG1 was similar, the level of IgG2a in the
pcDNA-BS vaccinated group was appreciably higher than that in
pcDNA-S immunized group.
ELISPOT assay was also used to assess the magnitudes of S-
specific IFN-c (Th1) and IL-4 (Th2) T-cell responses after the mice
were vaccinated with pcDNA-S or pcDNA-BS. Compared with
pcDNA-S immunization, antigen-specific IFN-c-secreting cell
number was 2-fold higher and IL-4-secreting cell number was 3
times higher in mice immunized with pcDNA-BS (P,0.05) (Fig. 8).
Moreover, in all groups, IFN-c was induced to a much higher level
than that of IL-4. Combing with the higher IgG2a elevated by BS
immunization, it is reasonable to draw a conclusion that BS protein
could induce a stronger Th1 bias immune response than S protein.
Discussion
The spike (S) protein of SARS CoV is a key protein involved in
viral entry and therefore the main target for vaccine design [32].
In the absence of S protein, expression of other structure proteins,
such as M and E proteins, does not induce a detectable
neutralizing antibody response [33]. Antibodies against SARS
CoV S protein inhibit pulmonary viral replication and protect
against SARS CoV challenge [34]. Variations in the S proteins
can dramatically affect the virulence and host tropism of the virus
[35,36]. For instance, SL-CoVs isolated from bats display greater
genetic variations than SARS CoVs from humans or civets [19].
Here, we intended to investigate whether the S protein of SL-CoV
isolated from bats can incorporate into viral like particles (VLPs)
formed by the E and M proteins of human SARS CoV and
whether such VLPs can activate DCs.
Using baculovirus expression system, we constructed BVLPs
incorporated with the E and M proteins of human SARS CoV and
the S protein of SL-CoV of bats. Electron microscopy (EM)
detection confirmed the formation of VLPs, which were very
similar to the morphology of the native virus. Western blot
indicated that BS protein was incorporated into BVLPs. Because
the major difference of S proteins between SARS CoV and SL-
CoV locates in the S1 region (,64%) and the S2 region is more
Figure 2. BVLPs induced phenotype changes in DCs. Immature DCs (10
6cells/ml) were incubated with 10 mg/ml of BVLPs, 10 mg/ml of LPS,
10 mg/ml of heated BVLPs, Ac (culture supernatant of sf21cells transfected with baculovirus expression vector pFastBac DUAL with gfp under the
control of p10 promoter) or PBS. 16 h post incubation, cells were collected, washed, stained with indicated antibodies, and analyzed by flow
cytometry. One representative experiment out of 3 is shown.
doi:10.1371/journal.pone.0002685.g002
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PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2685Figure 3. BVLPs induced secretion of cytokines in DCs. DCs were incubated with BVLPs (10 mg/ml), heated BVLPs (10 mg/ml), LPS (10 mg/ml),
Ac (culture supernatant of sf21 cells transfected with baculovirus expression vector pFastBac DUAL with gfp under the control of p10 promoter), or
PBS. BVLPs + PMB or LPS + PMB: 10 mg/ml BVLPs or 10 mg/ml LPS was treated with 10 mg/ml polymyxin B at room temperature for 1 h before
incubation with DCs. Following 16 h of treatment, supernatants were collected, and IL-6, IL-10 and TNF-a were analyzed using ELISA. Data are
expressed as the mean6SD of triplicate samples.
doi:10.1371/journal.pone.0002685.g003
VLPs of SL-CoV Stimulate DCs
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SL-CoV S protein into VLPs formed by the E and M proteins of
SARS CoV suggests that such BVLPs likely assembled through S2
region other than S1 region. These genome-free BVLPs formed by
structure proteins from different species provide us a physical
means to investigate their immunogenicity in immune cells.
SARS CoV mainly targets lung tissues and the clinical
syndrome of SARS indicates that the host immune system is
greatly damaged [37–39]. Dendritic cells (DCs) are antigen-
presenting cells that play key role in innate and adaptive immunity
[31,40–42]. Exposure of DCs to infectious SARS CoV leads to the
phenotypic and functional maturation of DCs, including costimu-
latory molecule expression, T cell-stimulation and cytokine
production. [43]. In addition, UV-inactivated SARS CoV also
activates immature DCs [44]. In this study, we have demonstrated
that BVLPs, morphologically and antigenically similar to the
native virus, exhibited stimulating ability in DCs and induced DC
maturation by enhancing the expression of cell-surface costimu-
latory molecules including those essential for optimal activation of
T cells: CD40, CD86, CD80 and CD83. Phenotypic maturation
Figure 4. Phenotypic characterization of DCs treated with BVLPs or with SARS CoV VLPs. DCs were incubated with SL-CoV BVLPs or SARS
CoV VLPs at a concentration of 10 mg/ml. DCs treated with LPS (10 mg/ml) and PBS were used as positive and negative control, respectively. The cells
were harvested at 16 h post-inoculation and the expression of CD40, CD86, CD83 and CD80 were analyzed by flow cytometry. Isotype-matched
controls were shown.
doi:10.1371/journal.pone.0002685.g004
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PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2685Figure 5. Cytokines secretions in DCs treated with BVLPs or with SARS CoV VLPs. DCs were incubated with SL-CoV BVLPs or SARS CoV
VLPs at a concentration of 10 mg/ml. DCs treated with LPS (10 mg/ml) and PBS were used as positive and negative control, respectively. After 16 h
incubation, supernatants were collected, and IL-6, IL10 and TNF-a were analyzed using ELISA. Data are expressed as the mean6SD of triplicate
samples.
doi:10.1371/journal.pone.0002685.g005
VLPs of SL-CoV Stimulate DCs
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incubated with lipopolysaccharide (LPS), a well-known stimulator
of DCs maturation. In contrast, heat-denatured BVLPs lost the
ability to enhance the expression of cell surface molecules and the
secretion of cytokine, suggesting that the specific structure of viral
proteins might significantly contribute to the immune modulating
activity. Taken together, our data indicate that the baculovirus
derived-BVLPs can interact with human DCs to induce DC
maturation and activation.
Our previous study found that VLPs formed by the S, E, and M
proteins of human SARS CoV elicited strong SARS CoV-specific
humoral and cellular immune responses in mice and conferred
protective immunity against the infection of S protein -pseudo-
typed murine leukemia viruses (MLV) [29]. Here, we showed that
both BVLPs and SARS CoV VLPs activated DCs and induced
DC maturation by enhancing the expression of costimulatory
molecules (CD40, CD86 and CD80) and the maturation marker
CD83. A study in SARS CoV-infected patients indicated that the
Figure 6. Evaluation of CD4 T cell types stimulated by BVLPs-exposed DCs. Immature DCs (1610
4) were exposed to BVLPs (10 mg/ml), Ac or
PBS for 24 h and then co-cultured with CD4+T cells (1610
5) in 96-well plates in triplicate for another 72 h. The DCs/T mixtures were then collected for
intracellular IFN-c or IL-4 staining followed by flow cytometry analysis. IFN-c and IL-4 positive populations in CD4 T cells were analyzed. Data are
expressed as the mean6SD of triplicate samples.
doi:10.1371/journal.pone.0002685.g006
Figure 7. Detection of SARS-CoV S-specific IgG and the subclasses in vaccinated mice. Mouse sera (8 per group) were collected 10 days
after the final immunization and assayed for IgG1 and IgG2a against the S2 protein of SARS-CoV. ELISA was used to detect the level of S-specific IgG
antibodies. Recombinant S2 protein expressed in E. Coli was purified and used as the detection antigen. Data are presented as means6SD.
doi:10.1371/journal.pone.0002685.g007
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stage and returned to normal after given adequate immunosup-
pressive treatment [45]. Corticosteroid has been used for the
treatment of SARS on the basis that proinflammatory cytokines is
responsible for the immunopathology in the lungs [46]. Of
interest, in the current study, BVLPs induced much higher levels
of IL-6 and TNF-a than did SARS CoV VLPs. It seemed that
BVLPs vs DCs served as a better model to simulate the acute-
phase response between the virus and the host. Thus, this model
may be applicable in the development of vaccines and drugs
against the virus. TNF-a and IL-6 are important proinflammatory
cytokines mediating apoptosis, immunity, and inflammation, and
may play important role in antiviral responses and inflammation
[31]. A previous study by Wang et al indicated that the S protein
of SARS CoV played a key role in the production of
proinflammatory cytokine at a stage of virus-host cell interaction.
S protein could activate NF-kB signaling pathway and thus up-
regulate the secretion of IL-6 and TNF-a. Here we demonstrate
that BVLPs are stronger immune modulators in terms of DC
activation and maturation. Since the only difference between
SARS CoV VLPs and BVLPs was the S protein incorporated, the
enhanced immune modulating ability of BVLPs is very likely
contributed by the S protein.
Different types of DCs may play different roles in the onset of a
Th1 or Th2 immune response. The balance between Th1 and
Th2 cells is important and may determine the outcome of an
immune response toward infection and allergy. We therefore
studied the influence of BVLPs-stimulated DCs on T cell
polarization by intracellular cytokine staining. Compared to
mock-treated DCs, BVLPs-exposed DCs increased the population
Figure 8. SARS-CoV S protein-specific IFN-c and IL-4 ELISPOT. The number of INF-c or IL-4 -secreting cells was assayed by ELISPOT using
splenocytes harvested from mouse spleens 10 days after the final immunization and stimulated in vitro with purified S2 protein. The results represent
the averages of triplicate wells of 3 mice and are expressed as means6SD. (A) SARS-CoV S protein-specific IFN-c-secreting cells. (B) SARS-CoV S
protein-specific IL-4-secreting cells.
doi:10.1371/journal.pone.0002685.g008
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was much higher than that of IL-4, indicating a bias of Th1
immune response. Because matured DCs can enhance native T
cells differentiation, these results further confirm that BVLPs can
induce DCs activation and maturation.
BVLPs had stronger ability to stimulate DCs by inducing the
production of IL-6 and TNF-a in our study. To address whether
such difference was S protein specific, we constructed two
recombinant plasmids pcDNA-S and pcDNA-BS, and detected
their immune responses in mice. The higher level of IgG2a and
the higher number of S protein-specific IFN-c or IL-4-secreting
cells in mice immunized with pcDNA-BS indicated that the S
protein of bat SL CoV was more immunogenic. Our in vivo data
provide evidence that the difference of immune modulating ability
between BVLPs and SARS-CoV VLPs was highly likely
contributed by the S protein.
Taken together, we have successfully constructed BVLPs
formed by membrane proteins of different origins, one from SL-
CoV isolated from bats (BS) and the other two (E and M) from
human SARS CoV. The formed BVLPs demonstrated stimulating
activity in immature DCs. In the absence of an in vitro cell culture
model for SL-CoV, our study has together demonstrated that
BVLPs vs DCs can be used as a model to study the interaction
between SL-CoV and host cells. Further study by using this model
may provide important information for vaccine development and
for understanding the pathogenesis and the evolution of SL-CoV.
Materials and Methods
Construction of plasmids and recombinant baculoviruses
DNAcoding the S protein (BS) of Bat SL-CoV was amplified from
Rp3 strain (GenBank accession number DQ071615) by reverse
transcription-polymerase chain reaction (RT-PCR) using the follow-
ing primers: 59-TTTGGATCCCCACCATGAAAATTTTAATT-
CTT and 59-GGG GAATTCTTATGTGTAGTGTAATTTTAC.
bs gene was cloned into pFastBac DUAL vector [47] under the
control of a strong viral promoter, polyhedron promoter. gfp gene was
cloned under the control of p10 promoter to generate pFBS.
Recombinant baculoviruses were generated using Autographa
californica multiple nucleopolyhedrovirus (AcMNPV) genome. In
brief, vAcBS was generated by transfecting the BS plasmids into
insect cells sf21 using Lipofectin (Invitrogen). Recombinant baculo-
v i r u sv A c M Ew a sg e n e r a t e da sp r e v i o u s l yd e s c r i b e d[ 3 0 ] .
In addition, s and bs gene were subcloned into pcDNA3.1(+)
(Invitrogen, Carlsbad, Calif.) to construct the recombinant
plasmids pcDNA-S and pcDNA-BS, respectively. The accuracy
of the constructs was confirmed by restriction digestion and
sequencing. DNA plasmids were purified using Qiagen MegaPrep
columns (Qiagen) and dissolved in endotoxin-free PBS to a final
concentration of 2 mg/ml and stored at 220uC.
Generation of SARS-CoV like particles containing BS
(BVLPs)
Insect cells were co-infected with vAcBS and vAcME at a
multiplicity of infection (moi) of 5. At 4 days post-infection, cells and
medium were harvested and centrifuged at 90,100 g for 4 hours.
BVLPsin the pellets were resuspended in PBS and further purified on
a discontinuous 30–50% (w/v) sucrose gradient. A visible band
between 30% and 40% sucrose layers was collected, concentrated by
centrifugation and then resuspended in PBS at a total protein
concentration of 2 mg/ml (measured in Eppendorf Biophotometer,
Germany). The purity of the VLPs was then checked by SDS-PAGE.
The presence of BS proteins in the purified preparations was
confirmed by western blot using rabbit-derived anti-SARS-CoV
antibody, kindly provided by Prof. Lin-Fa Wang in Australian
Animal Health Laboratory (B.T. Eaton and L.-F. Wang, unpublished
results). Immunogold labeling was detected using antiserum against
BS2 (667–1242 aa in S2 region of Bat S protein). To generate BS2
antiserum, the cDNA of 667–1242 aa in S2 region was cloned into
pMAL-c2x expression vector (NEB). BS2 protein was purified by
using Amylose Resins (NEB) and then was used to immunize rabbit.
Characterization of BVLPs by electron microscopy (EM)
For EM study of BVLPs budding from insect cells, Sf21 cells
were co-infected with vAcBS and vAcME at a MOI of 5. At 72 h
post-infection, the cells were collected and fixed with 2%
glutaraldehyde and then with 1% osmium tetroxide. Thin-section
samples were prepared and examined under a Hitachi-H7500
transmission electron microscope. For immunogold labeling,
BVLPs were loaded onto a collodion-coated EM grid for 5 min.
After removal of the excess sample solution, antibody against BS2
protein was added onto the grid and incubated for 1 h at room
temperature. Grids were washed three times and then incubated
with 15 nm gold conjugated anti-rabbit IgG for 1 h. The samples
were stained with 2% phosphotungstic acid (PTA) for 1 min, then
drained, and examined under the EM.
Culture of primary human dendritic cells (DCs)
Human peripheral blood mononuclear cells (PBMC) were
isolated from healthy donors by Isopaque-Ficoll (Lymphoprep;
Nycomed, Oslo, Norway) following the manufacturer’s instruc-
tions. Immature DCs were generated from PBMC as previously
described [48] with minor modifications. Briefly, PBMC in RPMI
1640 (Gibco Laboratories, Grand Island, NY) were cultured in six-
well plates (2610
6 cells/ml) for 2 hours. Adherent monocytes were
washed with RPMI 1640 and then cultured for 6 days in complete
medium containing 10% fetal calf serum (Life Technologies) and
supplemented with rhGM-CSF (1000 U/ml) and rhIL-4 (500 U/
ml) (both from Peprotech). Half of the medium was replaced every
two days. The resulting differentiated DCs were .97% CD1a
positive and ,1% CD14 positive.
Ethics
All participants gave written informed consent. This study was
conducted in accordance with the Declaration of Hubei and
approved by Health Department of Hubei Province and Wuhan
Blood Center of Hubei Province, China.
Stimulation of DCs with BVLPs
DCs (2610
6 cells) were incubated with either 10 mg/ml of
BVLPs or 10 mg/ml of lipopolysaccharide (LPS, Sigma, St. Louis,
MO). Meanwhile, immature DCs were treated with PBS, Ac
(culture supernatant of sf21 cells transfected with baculovirus
expression vector pFastBac DUAL with gfp under the control of
p10 promoter) or heat-denatured BVLPs (100uC for 10 min).
Alternatively, an equivalent amount of BVLPs or LPS was
incubated with 10 mg/ml polymyxin B (a compound that binds
to LPS and inactivates LPS’s biological functions [49]) at room
temperature for 1 h before added to DCs. After different
treatments of DCs at 37uC for 16 h, supernatants were removed
and frozen at 270uC until cytokine detection. DCs were stained
for specific cell-surface markers and analyzed by flow cytometry.
Assay of cytokines
Culture supernatants were collected for cytokine (TNF-a, IL-6
and IL-10) quantification using enzyme-linked immunosorbent
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CyTech, sensitivity: 2 pg/ml).
Flow cytometry
DC surface markers were analyzed by flow cytometry. Briefly,
cells were washed in cold PBS and cell surface staining was carried
out using the following antibodies: fluorescein isothiocyanate
(FITC)-conjugated anti-CD40, FITC-conjugated anti-CD80, phy-
coerythrin (PE)-conjugated anti-CD83, PE-conjugated anti-CD86
(all from PharMingen). After incubation with antibodies for
30 min at 4uC, cells were washed and analyzed using flow
cytometer (Beckman, EPICS ALTRA, USA). Data were analyzed
using EXOPO analysis software. A minimum of 10,000 events
were collected and analyzed for each sample. Isotype-matched
controls (PE-conjugated mouse-anti-human-IgG1, FITC-conju-
gated mouse-anti-human-IgG1, both from BD PharMingen) were
included in each staining.
Evaluation of T cell types stimulated by BVLPs-exposed
DCs
CD4+T cells were prepared from PBMC by positive selection
using anti-CD4 antibody (BD PharMingen) and the purity was
consistently above 95%. Immature DCs (1610
4) were exposed to
BVLPs (10 mg/ml), Ac or PBS for 24 h and washed thoroughly.
Treated DCs were then co-cultured with CD4+T cells (1610
5)i n
96-well plates (Costar) in triplicate for another 72 h. For
intracellular detection of IL-4 and IFN-c, DCs/T cell mixtures
were further stimulated with 10 ng/mL PMA (phorbol 12-
myristate 13-acetate) and 0.5 mmol/L ionomycin for 6 h. After
stimulation, mononsesin (1.5 ml/ml) was added to each well and
plates were incubated at 37uC for 3 h to block reaction. The cells
were then washed, fixed and permeabilized. Intracellular IFN-c
and IL-2 (both PE-conjugated) staining and flow cytometry
analysis (Beckman, EPICS ALTRA, USA) were performed in
succession. Data were analyzed using EXOPO analysis software.
A minimum of 10,000 events were collected and analyzed for each
sample. Isotype-matched controls (PE-conjugated mouse-anti-
human-IgG1, BD PharMingen) were included in each staining.
Analysis of the humoral immune response
6–8 wk-old female BALB/c mice were immunized intramus-
cularly with purified plasmid pcDNA-S or pcDNA-BS 3 times at a
2-wk interval. S-specific IgG and the subclasses (IgG1 and IgG2a)
in serum were assessed by ELISA. Recombinant S2 protein
expressed in E. Coli was purified and used as the detection antigen.
Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG,
IgG1 or IgG2a (sigma) was used as the secondary antibody.
Optical density (OD) was read at 490 nm (A490).
SARS-CoV S-specific ELISPOT assay
Cellular immune responses to SARS-CoV were assessed by
IFN-c and IL-4 ELISPOT assays using mouse splenocytes. Assays
were performed according to the instruction manual (U-CyTech,
Netherlands). Absorbance was read using an ELISPOT reader
(Hitech Instruments) and spot-forming cells (SFC) per 10
6
splenocytes were calculated. The medium background response
in the absence of antigen was consistently ,10 SFC per 10
6
splenocytes.
Statistical analysis
All data were presented as means6SD for the immunized mice
per group. The SPSS 13.0 software for windows was used for
statistical analysis. The LSD t-test was used for between group
comparisons. P values,0.05 were considered statistically signifi-
cant.
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